X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

X4 Pharmaceuticals (Nasdaq: XFOR) has announced significant inducement grants to three new executive officers under its 2019 Inducement Plan. The grants include stock options for 12.7 million shares issued on August 12, 2025, and additional 1.4 million shares on August 14, 2025.

The initial grants were distributed among Dr. Adam Craig, John Volpone (4.25 million shares each), and David Kirske (2.83 million shares) at $1.42 per share. Additional grants were issued at $3.14 per share following X4's $85 million private placement. The options feature varying vesting schedules over 18-36 months, subject to performance conditions and continued employment.

Positive

• Successful completion of $85 million private placement
• Strategic strengthening of executive team with three new officers
• Structured vesting schedules align management interests with long-term company goals

Negative

• Significant potential dilution from 14.1 million new stock options
• Substantial increase in stock-based compensation expense

News Market Reaction – XFOR

-12.63%

5 alerts

-12.63% News Effect

-12.6% Trough in 2 hr 35 min

-$5M Valuation Impact

$35.82M Market Cap

8.46K Volume

On the day this news was published, XFOR declined 12.63%, reflecting a significant negative market reaction. Argus tracked a trough of -12.6% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $5M from the company's valuation, bringing the market cap to $35.82M at that time.

Data tracked by StockTitan Argus on the day of publication.

BOSTON, Aug. 15, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on August 12, 2025, the company issued inducement awards to Adam Craig, M.D., John Volpone and David Kirske under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”), consisting of (i) options to purchase an aggregate of 4,250,718 shares of X4’s common stock granted to Dr. Craig, (ii) options to purchase an aggregate of 4,250,718 shares of X4’s common stock granted to Mr. Volpone and (iii) options to purchase an aggregate of 2,833,812 shares of X4’s common stock granted to Mr. Kirske. In addition, effective on August 14, 2025, the company issued additional inducement awards to Dr. Craig, Mr. Volpone and Mr. Kirske under the 2019 Inducement Plan, consisting of (i) options to purchase an aggregate of 529,201 shares of X4’s common stock granted to Dr. Craig, (ii) options to purchase an aggregate of 529,201 shares of X4’s common stock granted to Mr. Volpone and (iii) options to purchase an aggregate of 352,800 shares of X4’s common stock granted to Mr. Kirske.

These stock awards were granted as an inducement material to the new executive officers with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4’s Board of Directors. The awards issued on August 14, 2025 were intended to bring each grantee’s target ownership percentage following X4’s recent $85 million private placement to the percentage agreed to between the grantees and X4 during negotiation of the grantees’ initial compensation package.

The options issued on August 12, 2025 have a ten-year term and an exercise price of $1.42 per share, which is equal to the closing price of X4’s common stock on August 11, 2025. The options issued on August 14, 2025 have a ten-year term and an exercise price of $3.14 per share, which is equal to the closing price of X4’s common stock on August 14, 2025. The option granted to Dr. Craig and Mr. Volpone respectively will vest over a three-year period from August 12, 2025, with one-third of the shares vesting after 12 months and the remaining shares vesting monthly over the following 24 months, subject to certain performance conditions and the employee’s continued employment with X4 on such vesting dates. Certain of the options granted to Mr. Kirske will vest over an 18-month period from August 12, 2025, with one half of the shares vesting after 6 months and the remaining shares vesting monthly over the following 12 months, subject to certain accelerated vesting provisions and his continued employment with X4 on such vesting dates and certain of the options granted to Mr. Kirske will vest over three years, with one third of the shared vesting after 12 months and the remaining shares vesting monthly over the following 25 months, subject to certain performance conditions and the employee’s continued employee with X4 on such vesting dates. All of the options are subject to the terms and conditions of the 2019 Inducement Plan and the terms and conditions of an award agreement covering the grant.

About X4 Pharmaceuticals
X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare diseases of the immune system and significant unmet needs. Leveraging expertise in CXCR4 and immune system biology, X4 has successfully developed mavorixafor, an orally available CXCR4 antagonist that is currently being marketed in the U.S. as XOLREMDI^® in its first indication. The company is also evaluating additional uses of mavorixafor and is conducting a global, pivotal Phase 3 clinical trial (4WARD) in people with certain chronic neutropenic disorders. X4 is headquartered in Boston, Massachusetts. For more information, please visit www.x4pharma.com.

Investor Contact:
Candice Masse
astr partners
candice.masse@astrpartners.com
(978) 879-7273

FAQ

How many shares were granted in X4 Pharmaceuticals (XFOR) inducement awards?

A total of 14.1 million shares were granted, with 12.7 million shares on August 12, 2025, at $1.42 per share, and 1.4 million additional shares on August 14, 2025, at $3.14 per share.

What is the vesting schedule for XFOR's new executive stock options?

For Dr. Craig and Mr. Volpone, options vest over three years with one-third after 12 months and monthly thereafter. Mr. Kirske's options have split vesting schedules of 18 months and three years.

What was the purpose of X4 Pharmaceuticals' additional stock grants on August 14, 2025?

The additional grants were intended to adjust each grantee's target ownership percentage following X4's $85 million private placement to match previously agreed-upon levels.

Who are the recipients of XFOR's inducement grants?

The recipients are Dr. Adam Craig, John Volpone (4.25 million shares each), and David Kirske (2.83 million shares), who are new executive officers at X4 Pharmaceuticals.